CAMMA 3: A multicenter phase Ib trial evaluating the safety, pharmacokinetics, and activity of subcutaneous cevostamab monotherapy in patients with relapsed or refractory multiple myeloma.

Sosana Delimpasi, Hang Quach, Michele Cavo, P. Joy Ho, Cindy Lee, Armando Santoro, Rik Schots, Philip Vlummens, Dok Hyun Yoon, Sung-Soo Yoon, Cedric Dos Santos, Divya Samineni, Jiangeng Huang, Kristin Wehrman, Upen Patil, Semira Sheikh, Meletios A. Dimopoulos

Research output: Contribution to journalMeeting abstract (Journal)

Abstract

not available
Original languageEnglish
Pages (from-to)16-16
Number of pages1
JournalJournal of Clinical Oncology
Volume40
Issue number16
Publication statusPublished - 1 Jun 2022
Event2022 American Society of Clinical Oncology (ASCO) Annual Meeting: ASCO - , United States
Duration: 3 Jun 20227 Jun 2022

Fingerprint

Dive into the research topics of 'CAMMA 3: A multicenter phase Ib trial evaluating the safety, pharmacokinetics, and activity of subcutaneous cevostamab monotherapy in patients with relapsed or refractory multiple myeloma.'. Together they form a unique fingerprint.

Cite this